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A historical perspective on the 
FDA’s close scrutiny of vaccine use
Jane Kelly, MD 
Assistant State Epidemiologist 
Division of Acute Disease Epidemiology
Abdoulaye Diedhiou, MD, MS, PhD 
Director 
Division of Acute Disease Epidemiology
By mid-March 2021, the AstraZeneca SARS-
CoV-2 vaccine had been approved and was in use 
in more than 50 countries worldwide. Although 
some countries temporarily halted vaccine 
administration because of a possible association 
with an immune-mediated blood clotting disorder 
with thrombocytopenia, the rarity of the side effect 
prompted many countries to resume vaccination. 
German Chancellor Angela Merkel was publicly 
vaccinated with AstraZeneca. Yet the US would not 
even consider approving the AstraZeneca vaccine 
until US Phase 3 trials were complete. 
Why does the US Food and Drug Administration 
(FDA) demand this extra scrutiny and oversight 
of Phase 3 trials? Why delay access to a vaccine 
authorized for emergency use and, in some 
instances, approved for routine use in so many other 
countries, including in the UK and EU? The reason is, 
in part, historical.
Do you recognize the person with President John 
F. Kennedy below? She is Dr. Frances Kelsey, who 
President Kennedy awarded the Distinguished 
Federal Civilian Award. Why did she get the award?
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In 1960, a New Drug Application (NDA) was submitted 
to the FDA for thalidomide, an oral medication 
considered safe and effective in Europe for preventing 
nausea in pregnancy. The company anticipated 
quick approval. People were already planning how 
they were going to spend their expected Christmas 
bonuses when the drug was marketed in the US. Dr. 
Frances Kelsey was hired by the FDA in August 1960 
and assigned what was thought to be an easy first 
task: reviewing the thalidomide NDA.
Dr. Kelsey was not satisfied with the information 
as presented in the NDA and wanted more data 
on a medication that could affect the unborn child. 
Fortunately for the unborn babies in America who 
might have otherwise been exposed, she stood her 
ground amidst harsh criticism, public demand, and 
possibly pressure within the FDA itself. By 1961, 
data had accumulated indicating that thalidomide, 
administered during critical periods of fetal 
development, led to the tragic underdevelopment of 
limbs known as phocomelia.
Since that time, the FDA’s scrutiny of new 
pharmaceuticals has become more rigorous and 
new systems, such as the Vaccine Adverse Event 
Reporting System (VAERS), have increased sensitivity 
for detecting rare events. 
As of this writing, the European Medicines Agency 
is reviewing 167 cases of cerebral venous sinus 
thrombosis (CVST) and 53 cases of splanchnic 
thrombosis occurring after the administration of 34 
million doses of AstraZeneca vaccine. In the US, CDC 
and the FDA placed the Janssen vaccine on “pause” 
while they investigated 6 CVST cases and looked 
for others. Was this an over-abundance of caution? 
Public health is always a balancing act: What is 
an acceptable individual risk to protect population 
health? The question becomes even harder during a 
pandemic. 
Dr. Kelsey resolutely demanded robust data. While a 
great relief to morning sickness sufferers, thalidomide 
was not lifesaving, and taking more time to get 
adequate data was prudent. In contrast, some public 
health experts argue that pausing Janssen vaccine 
administration for an extremely rare complication was 
the wrong move: It slowed the race to herd immunity 
and may increase vaccine hesitancy.
The April 23, 2021, Advisory Committee for 
Immunization Practices (ACIP) vote to reaffirm the 
recommendation for Janssen vaccine use for all 
persons aged 18 years and older will become a 
classic ethics case study evoking the principles of 
Figure 1. Estimates of the number of cases of thrombosis with thrombocytopenia syndrome (TTS) and 
the number of deaths, ICU admissions, and hospitalizations prevented with the administration of the 
Janssen vaccine among US females, per 1 million doses of vaccine given (data as of April 21, 2021).
Source: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-04-23/06-COVID-Oliver-508.pdf 
Boy with phocomelia.  




1 Case of TTS
394 Deaths* Prevented
661 ICU Admissions* Prevented
2454 Hospitalizations* Prevented
* Deaths, ICU admissions, and deaths due to COVID-19
601 Hospitalizations* Prevented
7 Cases of TTS
6 Deaths* Prevented
56 ICU Admissions* Prevented
297 ospitalizations* Prevented
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beneficence, nonmaleficence, autonomy, and justice. 
As of April 21, 2021, a total of 15 cases of thrombosis 
with thrombocytopenia syndrome (TTS) associated 
with Janssen vaccine were uncovered, out of 7.98 
million doses administered; all were women and 
13/15 were under age 50. As seen in Figure 1, the 
risk for TTS was estimated at 7 cases/million doses 
for women aged <50, and <1 case/million doses for 
women aged 50+. Estimates for number of deaths, 
ICU admissions, and hospitalizations prevented 
supported the ethical principles of beneficence and 
non-maleficence (balancing benefits against risks) 
and argued for approval of the vaccine even for 
younger women.
The biggest issue was autonomy in the form of 
informed consent. Of the 15 voting ACIP members, 
10 voted for approval, 4 against, and 1 abstained. 
All who voted against agreed that Janssen should 
be reauthorized but expressed concern that not all 
young women would be adequately informed of the 
risk. 
Justice was also a concern: “I did not object to the 
recommendation; I objected to the absence of any 
kind of guidance from us,” Dr. Sarah Long, Drexel. 
“This is an age group that is most at risk (of TTS) 
that is getting a vaccine predominantly to save other 
people’s lives and morbidity—not their own.” 
A paragraph concerning the rare but increased risk of 
clotting events was added to the vaccine handout for 
patients and health care providers. Is that adequate? 
Would a more complicated recommendation be more 
confusing, increase vaccine suspicion, and ultimately 
lead to less vaccine uptake and more lives lost? If you 
were an ACIP voting member, what would you have 
recommended?
Additional Resources
1. Advisory Committee for Immunization Practices 
(ACIP) April 23, 2021 Presentation slides https://
www.cdc.gov/vaccines/acip/meetings/
slides-2021-04-23.html 
2. Principles of Clinical Ethics and Their Application 
to Practice https://www.karger.com/Article/
Pdf/509119 
Awareness of Multisystem 
Inflammatory Syndrome in 
Children (MIS-C) critical
Leigh Bragg, MD 
Physician - Medical Consultant 
Division of Acute Disease Epidemiology
Most children with COVID-19 infection have mild 
symptoms and excellent outcomes; however, there 
is a rare complication temporally associated with 
SARS-CoV-2 infection that occurs weeks after 
a child has been infected known as multisystem 
inflammatory syndrome in children (MIS-C). It was 
first identified in April 2020 in the United Kingdom 
and the Centers for Disease Control and Prevention 
(CDC) provided a case definition in May 2020.1,2
CDC defines MIS-C as:
• An individual aged <21 years presenting with fever 
for more than 24 hours, laboratory evidence of 
inflammation, and evidence of clinically severe 
illness requiring hospitalization, with multisystem 
(>2) organ involvement (cardiac, renal, respiratory, 
hematologic, gastrointestinal, dermatologic or 
neurological); AND
• No alternative plausible diagnoses; AND
• Positive for current or recent SARS-CoV-2 infection 
by RT-PCR, serology, or antigen test; or exposure 
to a suspected or confirmed COVID-19 case within 
the 4 weeks prior to the onset of symptoms.2
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Patients with MIS-C usually present with persistent 
fever, gastrointestinal symptoms, rash and 
mucocutaneous findings (Table 1).3,4 Gastrointestinal 
symptoms (nausea, vomiting, diarrhea) appear to be 
very common in children with MIS-C with rates up 
to 92%.1,3 However, symptoms of MIS-C may begin 
weeks after a patient is infected with SARS-CoV2 and 
may be vague or frequently missed. Some patients 
who develop MIS-C may not have had any COVID-19 
symptoms at the time of their initial infection. Most 
children with MIS-C require hospitalization and some 
develop severe disease with cardiac involvement, 
hemodynamic instability, and shock. 
Diagnosis of MIS-C requires laboratory evaluation, 
including tests for inflammation (CRP, ESR, 
fibrinogen, procalcitonin, d-dimer, ferritin, LDH, IL-6, 
complete blood cell count, albumin) and tests for 
current or previous SARS-CoV-2 infection (RT-PCR, 
antigen, serologic tests). Many patients also receive 
cardiac testing (echocardiogram, electrocardiogram, 
cardiac enzymes, B-type natriuretic peptide) and 
evaluations of other organ systems directed by the 
signs/symptoms of the patient.4,5
Treatment for MIS-C includes a multidisciplinary 
team that focuses on the inflammatory process and 
supportive measures. Immunomodulatory treatments 
with IVIG and steroids have been the mainstays of 
therapy as well as thromboprophylaxis with aspirin.5 
After discharge from the hospital, children typically 
will require follow up with subspeciality physicians.
In South Carolina, as of April 14, 2021, there have 
been 102 cases of MIS-C reported in children 
between 0 and 18 years. Their distribution is 
displayed by region in Figure 1 and by characteristics 
in Table 2. Of the 102 cases, 61.8% required intensive 
care unit admission and there have been 2 reported 
deaths. Hematologic (98%), cardiac (94.1%), and 
gastrointestinal (92.25%) involvement were the 
most common systems affected in the children 
in SC. Despite only representing approximately 
30% of SC’s children and adolescents, African 
Americans represented 52.9% of MIS-C cases. This 
disproportionate burden has also been seen in other 
studies across the US.1
MIS-C is a new condition that is reportable to 
the regional health department. As the COVID-19 
pandemic evolves through the utilization of vaccines 
in adults and new variants, awareness of MIS-C 
is critical as it is a serious and sometimes fatal 
complication of SARS-CoV-2 infection in children.
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Figure 1: Cases of MIS-C by region in South 
Carolina, as of April 14, 2021
Table 2: Characteristics of MIS-C Cases in South 
Carolina, as of April 14, 2021
PATIENT CHARACTERISTIC TOTAL NUMBER (%)
Male/Female 51 (51%)/51 (51%)
Black or African American 54 (52.9%)
White 35 (34.3%)









Table 1: Signs and Symptoms of MIS-C
• Fever
• Mucosal changes  
(conjunctivitis, oral lesions)
• Respiratory symptoms  




• Gastrointestinal symptoms  
(nausea, vomiting, diarrhea, 
abdominal pain)
• Cardiac symptoms  
(tachycardia, chest pain)
• Neurologic symptoms  
(headache, altered mental status)
• Rash
2021 School and Childcare 
Exclusion List
Alison Jamison-Haggwood, MSN, BSN, RN 
Director, Healthcare Associated Infections Section 
Division of Acute Disease Epidemiology
Natasha Sanders, RN, MSN 
Nurse Consultant 
Division of Acute Disease Epidemiology
The School and Childcare Exclusion List has 
routinely been updated annually and made available 
January 31 of each year. South Carolina Regulation 
61-20 requires that DHEC publish an Official 
School and Childcare Exclusion List of Contagious 
or Communicable Diseases to include specific 
conditions for the duration of school or childcare 
exclusion. 
These conditions and criteria 
apply to both students and 
staff. In 2019, the decision 
was made to update the 
School and Childcare 
Exclusion List for the start of 
each new school year. 
The current 2020 School 
and Childcare Exclusion 
List can be found on the 
DHEC website. A brochure 
for parents is also available on 
the website in English and Spanish.
Please contact the DHEC Division of Acute Disease 
Epidemiology (803-898-0861) with any questions 
about the School and Childcare Exclusion List.
Staying Home from School or Childcare When Your Child is Sick 
If you think that your child has an illness that can be spread to others, please keep him or her home from 
school or childcare. Contact your healthcare provider or clinic if you think medical attention is needed.
The School and Childcare Exclusion List was updated June 2021
Updated June 2021
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South Carolina Health Alert 
Network helps keep health care 
providers in the know
Shana Dorsey  
Health Alert Network Coordinator  
Bureau of Communicable Disease Prevention and Control
The South Carolina Health Alert Network (SCHAN) is 
a web-based emergency notification system used by 
DHEC to distribute health alerts and advisories from 
the Centers for Disease Control and Prevention (CDC) 
and DHEC. DHEC uses the SCHAN to notify health 
care providers of guidance, clusters, outbreaks, 
and other events of public health significance. The 
notifications are sent by email to organization-defined 
points of contact who then forward the message to 
appropriate recipients within their organization.
If you are a public health professional interested 
in receiving health alerts from the South Carolina 
Health Alert Network via email, you may sign up 
by completing a South Carolina Health Alert 
Network Registration Form. Once your registration 
is approved, your contact information will be added 
to the ReadyOp system, which is used to distribute 
health alerts.
Have you previously registered for SCHAN, but 
are no longer receiving health alerts? Your contact 
information may not be current, which could delay 
rapid alerts and notifications. If you would like to 
update your contact information, you may also 
complete a South Carolina Health Alert Network 
Registration Form. 
If you missed any of the previously distributed health 
alerts, you may visit the SCHAN webpage on the 
DHEC website at scdhec.gov/HAN.
Please email the DHEC Health Alert Network 
Coordinator at SCHAN@dhec.sc.gov with any 
questions about the South Carolina Health Alert 
Network.
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